March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical study results about its PVAD IQ at the 2026 Technology and Heart Failure Therapeutics (THT) Conference in Boston.
PVAD IQ is UltraSight’s FDA-cleared AI-powered software designed to assist healthcare providers manage patients who use microaxial flow pumps, a type of trans-aortic percutaneous ventricular assist device (PVAD). PVAD IQ uses machine learning algorithms to analyze ultrasound clips and measure structures to assure the PVAD is correctly placed.
In a validation study of 76 patients and 200 prospectively recorded echocardiographic loops, PVAD IQ achieved:
- Mean Absolute Error: 0.42 cm (95% CI 0.37-0.47)
- Met the pre-specified performance goal of a mean absolute error <0.5 cm
- Performance comparable to the intra-observer consistency of expert readers
The algorithm automatically identifies the aortic valve plane and pump inlet on transthoracic echocardiography and calculates insertion depth in centimeters – a measurement critical to optimizing device performance and minimizing complications.
Pump depth assessment is technically demanding and highly operator-dependent, particularly in ICU settings. By standardizing this measurement, PVAD IQ is designed to reduce variability, support faster bedside decisions, and extend expert-level assessment across care teams.
“These results demonstrate that UltraSight PVAD IQ achieves a level of precision and consistency that meaningfully addresses one of the most challenging and clinically relevant aspects of micro-axial flow pump management,” said Luca Baldetti, MD, Cardiac Intensive Care Unit, IRCCS San Raffaele Hospital, Milan, and principal investigator (PI) for the study. “In real-world cardiac intensive care environments, variability in measurement can directly impact clinical decision-making. An automated solution that performs at or above expert consistency has the potential to elevate standards of care and reduce the burden on highly specialized operators.”
“This Late-Breaking presentation marks an important validation of UltraSight PVAD IQ as more than a workflow tool; it is a precision technology designed to reduce variability, standardize assessment, and scale expertise across care teams,” said Ramya Singh, Chief Commercial Officer at UltraSight. “When AI can match and stabilize measurements that traditionally depend on operator experience, it opens the door to broader access, faster decisions, and more consistent outcomes in cardiac critical care.”
PVAD IQ integrates into existing ultrasound workflows as part of UltraSight's Echosystem, an AI-powered software platform designed to guide healthcare professionals in performing high-quality cardiac ultrasound exams, regardless of sonography proficiency or experience, thereby improving workflow efficiency and enhancing access to cardiac care.
For more information, visit the www.ultrasight.com
February 18, 2026 
